Hence, CPM has
been shown to predict the efficacy of duloxetine in treatment of
diabetic neuropathy [16]. However, a comprehensive
neurophysiological profile including the different levels and the
interaction between them has not been studied in DM patients with
peripheral neuropathy. Thus, in order to determine the degree of
generalized neuropathy in DM patients, we established a clinical
applicable platform providing the possibility of investigating coexisting
sensorimotor, autonomic and central neuropathies.